Daniel Feiler, MD
Ophthalmology · Lenexa, KSNPI 1245572916
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,129 of the $3,720 with a category attached, or 84.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,130, more than ten times the $95 reported in 2019.
Across 110 payments — averaging $33.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$757
- Notal Vision, Inc.$591
- ANI Pharmaceuticals, Inc.$454
- Alimera Sciences, Inc.$446
- AbbVie$424
- Genentech USA, Inc.$340
- plus $708 from 9 others
Across 6 payments — averaging $4304.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$26K
What the payments were for
- Speaking & faculty fees$59116%
- Food & beverage$3,12984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 21 | $757 |
| Notal Vision, Inc. | 1 | $591 |
| ANI Pharmaceuticals, Inc. | 14 | $454 |
| Alimera Sciences, Inc. | 16 | $446 |
| AbbVie | 24 | $424 |
| Genentech USA, Inc. | 13 | $340 |
| Apellis Pharmaceuticals, Inc. | 5 | $245 |
| Astellas Pharma US Inc | 5 | $181 |
| Regeneron | 1 | $83 |
| Biogen | 3 | $74 |
| Eyepoint US, Inc. | 2 | $35 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $28 |
| Novartis | 1 | $23 |
| Harrow Eye, LLC | 1 | $21 |
| Alcon | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,720 in reported general payments places this provider in the 75th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 44 | $5,432 |
| Prednisolone Acetate | 142 | $4,584 |
| Ofloxacin | 97 | $1,053 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $901 |
| Atropine Sulfate | 12 | $410 |
| Brimonidine Tartrate | 19 | $371 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $360 |
| Latanoprost | 14 | $164 |
| Timolol Maleate | 32 | $134 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lenexa
- Blake CooperLenexa$100K
- Michael EllisLenexa$38K
- Ivan BatlleLenexa$8K
- David DyerLenexa$6K
- Steven CohenLenexa$4K
- Gregory FoxLenexa$3K
- Ravi SinghLenexa$2K
- Beatty SuiterLenexa$2K
- Nish PatelLenexa$2K
- Daniel DurrieOverland Park$974K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.